HEC96719
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C29H22Cl2N2O5 |
| Molar mass | 549.40 g·mol−1 |
HEC96719 is a tricyclic farnesoid X receptor agonist developed for non-alcoholic steatohepatitis.[1][2][3]
References[edit]
- ^ Cao, Shengtian; Yang, Xinye; Zhang, Zheng; Wu, Junwen; Chi, Bo; Chen, Hong; Yu, Jianghong; Feng, Shanshan; Xu, Yulin; Li, Jing; Zhang, Yingjun; Wang, Xiaojun; Wang, Yan (February 2022). "Discovery of a tricyclic farnesoid X receptor agonist HEC96719, a clinical candidate for treatment of non-alcoholic steatohepatitis". European Journal of Medicinal Chemistry. 230: 114089. doi:10.1016/j.ejmech.2021.114089. PMID 34998040. S2CID 245577605.
- ^ Zhang, Na; Fan, Tianyun; Zhao, Liping; Li, Yiming; Bao, Yunyang; Ma, Xican; Mei, Yuheng; Wang, Yanxiang; Liu, Yonghua; Deng, Hongbin; Li, Yinghong; He, Hongwei; Song, Danqing (January 2023). "Discovery and development of palmatine analogues as anti-NASH agents by activating farnesoid X receptor (FXR)". European Journal of Medicinal Chemistry. 245 (Pt 1): 114886. doi:10.1016/j.ejmech.2022.114886. PMID 36347091. S2CID 253329947.
- ^ Lu, Ran; Liu, Ye; Hong, Tianpei (April 2023). "Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review". Diabetes, Obesity and Metabolism. 25 (S1): 13–26. doi:10.1111/dom.15014. PMID 36775938. S2CID 256825486.